An interventional study of Smartwatch - all data and Portable holter system in Heart Diseases, Atrial Fibrillation (AF) and Angina, Unstable, sponsored by University of Sao Paulo. Recruiting at 1 site in Brazil. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2025-09-15.
Sponsored by University of Sao Paulo · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies in Heart Diseases with a site in Brazil — 11 open to participants now, 12 under way, 3 of them phase 3. Heart Diseases · Brazil.
Among the 48 studies in Heart Diseases with a site in Brazil, this one is the 17th largest by planned enrollment of the 44 interventional ones that give a count, is one of 5 that started in 2025, is one of 21 with no phase, reaches primary completion later than 3 of the 11 other live ones, and was the 45th registered.
2,135 studies on the registry are indexed under Heart Diseases; 250 are open to participants now.
Browse Heart Diseases studies →11 of the 48 studies in Heart Diseases with a site in Brazil are open now. Recruiting first, the newest first:
Lexeo Therapeutics · Sites in Brazil, United States, Canada and 6 more countries
Ages 6+
Eli Lilly and Company · Sites in Brazil, Argentina, Australia and 35 more countries
Ages 50+
Lexeo Therapeutics · Sites in Brazil, United States, Canada and 5 more countries
Ages 6+
Abbott Medical Devices · Sites in Brazil, France, Germany and 6 more countries
Ages 18+
Eidos Therapeutics, a BridgeBio company · Sites in Brazil, United States, Argentina and 21 more countries
Ages 18–75
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 182 Heart Diseases studies recruiting now, 128 (70%) set no upper age limit and 22 (12%) stop at 75 or younger; 33 take children under 18; 41 take healthy volunteers.
This study: 22 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 16 · Phase 4 5
First in 2004; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 520 is above the median of 129 across 931 interventional studies indexed under Heart Diseases.
Median enrollment 274 across the 44 interventional studies, 297 across the 4 observational. Of the 29 that completed or were terminated, 13 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 48 have an industry lead sponsor. The 10 most frequent:
University of Sao Paulo is the lead sponsor of 1,036 studies on the registry; 96 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
University of Sao Paulo has 5 studies filed under Heart Diseases — fewer than ten, so there is no comparison to draw.
2 of the studies in Heart Diseases with a site in Brazil that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07217392Abbott Medical DevicesLeft Bundle Branch Area Pacing (LBBAP) PMCF Study | 2027-04-30 |
| NCT06865482Lexeo TherapeuticsClinical Course Of Disease In Participants With FA-CM | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 48 studies in Heart Diseases with a site in Brazil, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The FAPO-2 study (Patient Monitoring Tool for Clinical Observation and Arrhythmia Detection) is a prospective, interventional, non-randomized study designed to evaluate the feasibility, usability, clinical effectiveness, and cost-efficiency of a wearable-enabled remote monitoring strategy in adult cardiac patients. The intervention consists of active clinical management of patients via teleconsultations, triggered by automated alerts generated through wearable data integrated into a centralized digital platform. FAPO-2 will include patients with chronic cardiovascular conditions and those undergoing recent minimally invasive interventions. The central objective is to validate a structured model for early arrhythmia detection, remote risk stratification, and timely clinical action. A total of 520 patients aged ≥22 years will be enrolled, stratified by sex (1:1), and followed at the Heart Institute (InCor) of the University of São Paulo. Participants will be allocated into one of four protocol groups:
Group 1 - Pilot (n=15): Healthy volunteers monitored for \~14±3 days using both the smartwatch and a portable holter system to validate usability, skin tolerability, signal integrity, and data flow within the platform.
Group 2 - Extensive Outpatient Monitoring (n=150): Patients with chronic cardiovascular diseases monitored over a 45-day period. During 30 days, monitoring will be performed using a smartwatch to capture blood pressure, oxygen saturation, heart rate, and single-lead ECG. For 15 days, participants will use both the smartwatch (for HR and ECG) and a portable holter system.
Group 3 - Extensive Post-Intervention Monitoring (n=50): Patients recently undergoing procedures such as angioplasty, TAVI, or ablation, following the same monitoring protocol as Group 2.
Group 4 - Optimized Outpatient Monitoring (n=305): Patients with stable chronic cardiac disease monitored for 15±3 days, using both devices simultaneously for HR and ECG (smartwatch) and portable holter system.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy volunteers monitored for \~14±3 days using both a smartwatch and a portable holter system to validate usability, skin tolerability, signal integrity, and data flow within the platform.
Device: Smartwatch - all data · Device: Portable holter system · Procedure: Telemonitoring · Other: AI Model Development
Patients with chronic cardiovascular diseases monitored over 45±3 days. For 30 days, participants use the smartwatch to collect blood pressure, oxygen saturation (SpO2), heart rate (HR), and sigle-lead ECG. Also, for 15 days, participants use both smartwatch (HR and ECG only) and portable holter system simultaneously, with the patch providing continuous ECG monitoring.
Device: Smartwatch - all data · Device: Portable holter system · Procedure: Telemonitoring · Other: AI Model Development
Patients who have recently undergone minimally invasive cardiovascular procedures such as angioplasty, transcatheter aortic valve implantation (TAVI), or catheter ablation. Monitoring occurs over 45±3 days. For 30 days, participants use the smartwatch to collect blood pressure, oxygen saturation (SpO2), heart rate (HR), and single-lead ECG. Also, for 15 days, both the smartwatch (HR and ECG only) and the portable holter system are used simultaneously, with the portable holter system providing continuous ECG monitoring.
Device: Smartwatch - all data · Device: Portable holter system · Procedure: Telemonitoring · Other: AI Model Development
Patients with stable chronic cardiac disease monitored for 15±3 days using both the smartwatch captures heart rate and single-lead ECG, while the portable holter system provides continuous ECG monitoring.
Device: Portable holter system · Procedure: Telemonitoring · Other: AI Model Development · Device: Smartwatch - ECG and HR
Single-lead ECG, blood pressure (BP), oxygen saturation (SpO2), and continuous heart rate (HR).
continuous ECG monitoring for 14 days for comparison with the data from the smartwatch
Remote consultations triggered by critical alerts based on predefined thresholds.
Data analysis using artificial intelligence for prioritization of patients based on health data collected from wearables.
Single-lead ECG and continuous heart rate (HR)
Incidence and number of Atrial Fibrillation (AF) events detected
Incidence and total number of AF events detected, stratified by study group and device type (smartwatch, portable Holter). This allows assessment of AF detection rate across different monitoring protocols and devices during the follow-up period.
Time frame: During the monitoring period for each group, as specified (14-45 days depending on group)
Number of critical health alerts generated by the FAPO-SI³ platform
Alerts categorized by physiological parameter: blood pressure (BP), heart rate (HR), and oxygen saturation (SpO₂). Mean clinical response time to alerts will be calculated per patient during their respective monitoring period, allowing assessment of platform responsiveness and clinical workflow efficiency.
Time frame: During the monitoring period for each group, as specified (14-45 days depending on group)
Patient risk classification generated by the AI model
Distribution of patients across AI-generated risk categories (e.g., low, moderate, high) based on physiological and biometric data collected from the smartwatch and portable Holter system during the monitoring period.
Time frame: During the monitoring period for each group, as specified (14-45 days depending on group)
Patient risk classification generated by the AI model
Distribution of patients across AI-generated risk categories adapted from the Manchester Triage System. The algorithm will classify patients into risk levels (e.g., immediate, very urgent, urgent, standard, non-urgent) based on physiological and biometric data collected from the smartwatch and portable Holter system during the monitoring period.
Time frame: During the monitoring period for each group, as specified (14-45 days depending on group)
Adverse events related to device use
Incidence of device-related adverse events including skin lesions (MARSI), allergic reactions, and discomfort (graded using validated scales) reported during the monitoring period.
Time frame: From enrollment through the monitoring period, up to 45 days depending on study group
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Participant monitoring will be conducted by the multidisciplinary team via the SI³ platform, allowing near real-time detection of clinical events and prompt intervention. After study completion, all data will be anonymized and analyzed by the InCor team. De-identified datasets may be shared with the sponsor and affiliated entities. No personally identifiable information will be disclosed. All data sharing will comply with ethical and legal data protection standards.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Individual participant data (IPD) and supporting documentation will be made available exclusively to the study sponsor following the completion of the clinical study. There is no defined end date, as the sponsor will assume full custodianship of the data upon transfer. No public sharing of the data is planned.
Access criteria: Access to IPD and supporting information will be restricted to the study sponsor, in accordance with contractual agreements and applicable data protection regulations. The sponsor will have full authority over data access, management, and potential secondary use.
Started Feb 2025 (actual). Primary completion is estimated for Jan 2026, 11 months after the start.
Of 264 non-industry interventional studies with no phase under Heart Diseases, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 51. This study's planned 11 months is below that.
Counting every sponsor, half of 337 studies reached it within 25 months; a quarter within 11 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.